Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 200 av 220 resultater
Tid
Selskap
Tittel
Sektor
Kategori
02 Jun 2022
22:15 CEST
NANOBIOTIX
L’ASSEMBLÉE GÉNÉRALE MIXTE ANNUELLE DE NANOBIOTIX SE TIENDRA LE 23 JUIN 2022
20103010 Biotechnology
Other subject
19 May 2022
03:12 CEST
NANOBIOTIX
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
20103010 Biotechnology
Other subject
19 May 2022
03:12 CEST
NANOBIOTIX
CORRIGE ET REMPLACE : NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER TRIMESTRE
20103010 Biotechnology
Other subject
18 May 2022
22:40 CEST
NANOBIOTIX
NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER TRIMESTRE
20103010 Biotechnology
Other subject
18 May 2022
22:40 CEST
NANOBIOTIX
NANOBIOTIX Provides First Quarter Operational and Financial Update
20103010 Biotechnology
Other subject
17 May 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX PARTICIPERA EN JUIN À LA CONFÉRENCE JEFFERIES HEALTHCARE
20103010 Biotechnology
Other subject
17 May 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
20103010 Biotechnology
Other subject
11 May 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX PARTICIPERA PROCHAINEMENT À DEUX CONFÉRENCES INVESTISSEURS
20103010 Biotechnology
Other subject
11 May 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
20103010 Biotechnology
Other subject
10 May 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
10 May 2022
22:15 CEST
NANOBIOTIX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
04 May 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX ANNONCERA SES RÉSULTATS FINANCIERS DU PREMIER TRIMESTRE 2022, LE 18 MAI 2022
20103010 Biotechnology
Other subject
04 May 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
20103010 Biotechnology
Other subject
02 May 2022
22:15 CEST
NANOBIOTIX
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
20103010 Biotechnology
Other subject
02 May 2022
22:15 CEST
NANOBIOTIX
DE NOUVELLES DONNÉES SUR NBTXR3, PRODUIT CANDIDAT PRINCIPAL DE NANOBIOTIX, SERONT PRÉSENTÉES LORS DE LA RÉUNION ANNUELLE DE L'ASCO 2022
20103010 Biotechnology
Other subject
11 Apr 2022
22:15 CEST
NANOBIOTIX
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
20103010 Biotechnology
Other subject
11 Apr 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX : DE NOUVELLES DONNÉES PRÉCLINIQUES EN IMMUNOTHÉRAPIE MONTRENT UNE ACTIVATION IMMUNE ANTI-TUMORALE DU TRIPLE BLOCAGE PD-1, LAG-3 ET TIGIT RENFORCÉE LORSQU'IL EST ASSOCIÉ À NBTXR3 ACTIVÉ PAR RADIOTHÉRAPIE
20103010 Biotechnology
Other subject
08 Apr 2022
23:57 CEST
NANOBIOTIX
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
20103010 Biotechnology
Other subject
08 Apr 2022
23:57 CEST
NANOBIOTIX
NANOBIOTIX ANNONCE AVOIR DÉPOSÉ SON DOCUMENT D’ENREGISTREMENT UNIVERSEL 2021 CONTENANT LE RAPPORT FINANCIER ANNUEL ET SON « FORM 20-F » 2021
20103010 Biotechnology
Other subject
07 Apr 2022
22:15 CEST
NANOBIOTIX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
07 Apr 2022
22:15 CEST
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
30 Mar 2022
22:21 CEST
NANOBIOTIX
NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR L’ANNÉE 2021
20103010 Biotechnology
Other subject
30 Mar 2022
22:21 CEST
NANOBIOTIX
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
20103010 Biotechnology
Other subject
08 Mar 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
08 Mar 2022
22:15 CET
NANOBIOTIX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
10 Feb 2022
22:15 CET
NANOBIOTIX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
New
10 Feb 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
New
09 Feb 2022
22:15 CET
NANOBIOTIX
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
20103010 Biotechnology
New
09 Feb 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX ANNONCE LA PUBLICATION DE L’ÉTUDE D’UN PREMIER CAS CLINIQUE DE TRAITEMENT PAR NBTXR3 DANS LE CANCER DU PANCRÉAS
20103010 Biotechnology
New
26 Jan 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
20103010 Biotechnology
Other subject
26 Jan 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX ANNONCE LA PUBLICATION DE NOUVELLES DONNÉES PRÉCLINIQUES DÉCRIVANT LE POTENTIEL DE LA COMBINAISON DE NBTXR3 AVEC LES IMMUNOTHÉRAPIES PAR ANTI-PD-1 ET ANTI-CTLA-4
20103010 Biotechnology
Other subject
11 Jan 2022
22:15 CET
NANOBIOTIX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
11 Jan 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
10 Jan 2022
08:00 CET
NANOBIOTIX
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
20103010 Biotechnology
Meetings / events
10 Jan 2022
08:00 CET
NANOBIOTIX
NANOBIOTIX ACTUALISE SES PRINCIPAUX OBJECTIFS ET FAIT LE POINT SUR SES ACTIVITÉS PRÉVUES EN 2022
20103010 Biotechnology
Meetings / events
05 Jan 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX ANNONCE LE RECRUTEMENT DU PREMIER PATIENT DE L'ÉTUDE NANORAY-312, ÉTUDE MONDIALE DE PHASE III ET D'ENREGISTREMENT DE NBTXR3 DANS LES CANCERS DE LA TÊTE ET DU COU
20103010 Biotechnology
Other subject
05 Jan 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
20103010 Biotechnology
Other subject
04 Jan 2022
22:15 CET
NANOBIOTIX
NANOBIOTIX ANNONCE SA PARTICIPATION À TROIS CONFÉRENCES VIRTUELLES INVESTISSEURS EN JANVIER 2022
20103010 Biotechnology
Other subject
04 Jan 2022
22:15 CET
NANOBIOTIX
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
20103010 Biotechnology
Other subject
08 Dec 2021
22:15 CET
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other financial transaction
08 Dec 2021
22:15 CET
NANOBIOTIX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other financial transaction
17 Nov 2021
22:15 CET
NANOBIOTIX
NANOBIOTIX INTERVIENDRA LORS DE LA QUATRIÈME EVERCORE ISI HEALTHCONX CONFERENCE
20103010 Biotechnology
Other subject
17 Nov 2021
22:15 CET
NANOBIOTIX
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
20103010 Biotechnology
Other subject
09 Nov 2021
22:15 CET
NANOBIOTIX
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
20103010 Biotechnology
Other subject
09 Nov 2021
22:15 CET
NANOBIOTIX
NANOBIOTIX ANNONCE DE NOUVELLES DONNÉES PRÉCLINIQUES MONTRANT L’AMORÇAGE IMMUNITAIRE ET LE POTENTIEL DE LA COMBINAISON DE NBTXR3 AVEC DES INHIBITEURS DE CHECKPOINTS
20103010 Biotechnology
Other subject
08 Nov 2021
22:15 CET
NANOBIOTIX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
08 Nov 2021
22:15 CET
NANOBIOTIX
NANOBIOTIX : INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
20103010 Biotechnology
Other subject
03 Nov 2021
21:15 CET
NANOBIOTIX
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
20103010 Biotechnology
Other subject
03 Nov 2021
21:15 CET
NANOBIOTIX
NANOBIOTIX INTERVIENDRA LORS DE LA JEFFERIES LONDON HEALTHCARE CONFERENCE
20103010 Biotechnology
Other subject
24 Oct 2021
23:02 CEST
NANOBIOTIX
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
20103010 Biotechnology
Meetings / events
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva